GlassScriptPhysician profile
Brandon Bader
NPI 1710364377
$6,598.93
in general payments reported to CMS, 2019-2025
22 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,803 · 2023: $1,598 · 2024: $1,880 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,337 · Travel and Lodging: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,336.59 |
| Travel and Lodging | $458.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,716.84 | 2022-2025 | Bodyguardian, Watchman Flx, Avvigo Guidance System |
| Abiomed | $1,026.72 | 2023-2025 | Impella |
| Terumo Medical Corporation | $828.97 | 2023-2025 | Glidesheath Slender, Glidewire, Angio-Seal |
| Amgen INC. | $428.19 | 2023-2024 | Repatha |
| Medtronic, INC. | $417.15 | 2022-2025 | Micra, Abre, Avalus |
| E.R. Squibb & Sons, L.L.C. | $266.94 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $261.28 | 2023-2025 | Lifevest |
| Abbott Laboratories | $227.55 | 2025 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.65 | 2023-2024 | Jardiance |
| Pfizer INC. | $209.96 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $173.06 | 2023-2025 | |
| Cardiovascular Systems INC. | $144.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $142.45 | 2023-2025 | |
| Imperative Care, INC | $110.42 | 2025 | Symphony Catheter |
| Scpharmaceuticals INC. | $87.57 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $81.99 | 2024 | Inpefa |
| Stryker Corporation | $76.36 | 2025 | Flowtriever |
| Biosense Webster, INC. | $70.17 | 2025 | Carto 3 |
| Cleerly, INC. | $49.78 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Baxter Healthcare | $29.87 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $19.22 | 2023 | Nexletol |
| Cardiva Medical, INC. | $13.81 | 2023 | Cardiva Vascade 6/7f Vcs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.